The vagus nerve and the inflammatory reflex - Linking immunity and metabolism

Nature Reviews Endocrinology

Volumn 8, Issue 12, 2012, Pages 743-754

  Pavlov, Valentin A ^a   Tracey, Kevin J ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NICOTINIC RECEPTOR; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR;

BODY WEIGHT; CD4+ T LYMPHOCYTE; CHOLINERGIC STIMULATION; CYTOKINE PRODUCTION; DIETARY INTAKE; ENDOTOXEMIA; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HUMAN; HYPERGLYCEMIA; IMMUNE FUNCTION TEST; IMMUNITY; INFLAMMATION; INSULIN RESISTANCE; LIPID DIET; METABOLIC REGULATION; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; VAGUS NERVE;

ANIMALS; DIABETES MELLITUS, TYPE 2; HOMEOSTASIS; HUMANS; INFLAMMATION; METABOLIC NETWORKS AND PATHWAYS; OBESITY; REFLEX; SIGNAL TRANSDUCTION; VAGUS NERVE;

EID: 84870038215     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2012.189     Document Type: Review

References (142)

1. Tracey, K. J. The inflammatory reflex. Nature 420, 853-859 (2002).
2. Tracey, K. J. Reflex control of immunity. Nat. Rev. Immunol. 9, 418-428 (2009).
3. Andersson, U. & Tracey, K. J. Reflex principles of immunological homeostasis. Annu. Rev. Immunol. 30, 313-335 (2011).
4. Baccala, R. et al. Sensors of the innate immune system: their mode of action. Nat. Rev. Rheumatol. 5, 448-456 (2009).
5. Chen, G. Y. & Nunez, G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 10, 826-837 (2010).
6. Andersson, U. & Tracey, K. J. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 29, 139-162 (2011).
7. Medzhitov, R. Inflammation 2010: new adventures of an old flame. Cell 140, 771-776 (2010).
8. Pavlov, V. A. & Tracey, K. J. The cholinergic anti-inflammatory pathway. Brain Behav. Immun. 19, 493-499 (2005).
9. Tracey, K. J. Physiology and immunology of the cholinergic antiinflammatory pathway. J. Clin. Invest. 117, 289-296 (2007).
10. Pavlov, V. A. Cholinergic modulation of inflammation. Int. J. Clin. Exp. Med. 1, 203-212 (2008).
11. Bastard, J. P. et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 17, 4-12 (2006).
12. Donath, M. Y. & Shoelson, S. E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11, 98-107 (2011).
13. Hotamisligil, G. S. Inflammation and metabolic disorders. Nature 444, 860-867 (2006).
14. Richter, W. O., Geiss, H. C., Aleksic, S. & Schwandt, P. Cardiac autonomic nerve function and insulin sensitivity in obese subjects. Int. J. Obes. Relat. Metab. Disord. 20, 966-969 (1996).
15. Karason, K., Molgaard, H., Wikstrand, J. & Sjostrom, L. Heart rate variability in obesity and the effect of weight loss. Am. J. Cardiol. 83, 1242-1247 (1999).
16. Ziegler, D. et al. Selective contribution of diabetes and other cardiovascular risk factors to cardiac autonomic dysfunction in the general population. Exp. Clin. Endocrinol. Diabetes 114, 153-159 (2006).
17. Carnethon, M. R., Jacobs, D. R. Jr, Sidney, S. & Liu, K. Influence of autonomic nervous system dysfunction on the development of type 2 diabetes: the CARDIA study. Diabetes Care 26, 3035-3041 (2003).
18. Marrero, M. B. et al. An α7 nicotinic acetylcholine receptor-selective agonist reduces weight gain and metabolic changes in a mouse model of diabetes. J. Pharmacol. Exp. Ther. 332, 173-180 (2010).
19. Wang, X., Yang, Z., Xue, B. & Shi, H. Activation of the cholinergic antiinflammatory pathway ameliorates obesity-induced inflammation and insulin resistance. Endocrinology 152, 836-846 (2011).
20. Satapathy, S. K. et al. Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice. Mol. Med. 17, 599-606 (2011).
21. Borovikova, L. V. et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405, 458-462 (2000).
22. Wang, H. et al. Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation. Nature 421, 384-388 (2003).
23. Pavlov, V. A., Wang, H., Czura, C. J., Friedman, S. G. & Tracey, K. J. The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Mol. Med. 9, 125-134 (2003).
24. Goehler, L. E. et al. Vagal immune-to-brain communication: a visceral chemosensory pathway. Auton. Neurosci. 85, 49-59 (2000).
25. Niijima, A. The afferent discharges from sensors for interleukin 1β in the hepatoportal system in the anesthetized rat. J. Auton. Nerv. Syst. 61, 287-291 (1996).
26. Ek, M., Kurosawa, M., Lundeberg, T. & Ericsson, A. Activation of vagal afferents after intravenous injection of interleukin-1β: role of endogenous prostaglandins. J. Neurosci. 18, 9471-9479 (1998).
27. Goehler, L. E. et al. Interleukin-1β in immune cells of the abdominal vagus nerve: a link between the immune and nervous systems? J. Neurosci. 19, 2799-2806 (1999).
28. Hansen, M. K., O'Connor, K. A., Goehler, L. E., Watkins, L. R. & Maier, S. F. The contribution of the vagus nerve in interleukin-1β-induced fever is dependent on dose. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280, R929-R934 (2001).
29. Pavlov, V. A. & Tracey, K. J. Neural regulators of innate immune responses and inflammation. Cell. Mol. Life Sci. 61, 2322-2331 (2004).
30. Hosoi, T., Okuma, Y., Matsuda, T. & Nomura, Y. Novel pathway for LPS-induced afferent vagus nerve activation: possible role of nodose ganglion. Auton. Neurosci. 120, 104-107 (2005).
31. de Lartigue, G., Barbier, de la Serre, C., Espero, E., Lee, J. & Raybould, H. E. Diet-induced obesity leads to the development of leptin resistance in vagal afferent neurons. Am. J. Physiol. Endocrinol. Metab. 301, E187-E195 (2011).
32. Guarini, S. et al. Adrenocorticotropin reverses hemorrhagic shock in anesthetized rats through the rapid activation of a vagal anti-inflammatory pathway. Cardiovasc. Res. 63, 357-365 (2004).
33. Pavlov, V. A. et al. Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. Proc. Natl. Acad. Sci. USA 103, 5219-5223 (2006).
34. Pavlov, V. A. et al. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav. Immun. 23, 41-45 (2009).
35. Lee, S. T. et al. Cholinergic anti-inflammatory pathway in intracerebral hemorrhage. Brain Res. 1309, 164-171 (2010).
36. Pavlov, V. A. et al. Selective α7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit. Care Med. 35, 1139-1144 (2007).
37. Parrish, W. R. et al. Modulation of TNF release by choline requires α7 subunit nicotinic acetylcholine receptor-mediated signaling. Mol. Med. 14, 567-574 (2008).
38. Gallowitsch-Puerta, M. & Pavlov, V. A. Neuro-immune interactions via the cholinergic anti-inflammatory pathway. Life Sci. 80, 2325-2329 (2007).
39. Olofsson, P. S. et al. α7 nicotinic acetylcholine receptor (α7nAChR) expression in bone marrow-derived non-T cells is required for the inflammatory reflex. Mol. Med. 18, 539-543 (2012).
40. Hamano, R. et al. Stimulation of α7 nicotinic acetylcholine receptor inhibits CD14 and the tolllike receptor 4 expression in human monocytes. Shock 26, 358-364 (2006).
41. Guarini, S. et al. Efferent vagal fibre stimulation blunts nuclear factor-κB activation and protects against hypovolemic hemorrhagic shock. Circulation 107, 1189-1194 (2003).
42. Pavlov, V. A. & Tracey, K. J. Controlling inflammation: the cholinergic anti-inflammatory pathway. Biochem. Soc. Trans. 34, 1037-1040 (2006).
43. de Jonge, W. J. et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat. Immunol. 6, 844-851 (2005).
44. Rosas-Ballina, M. et al. Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proc. Natl Acad. Sci. USA 105, 11008-11013 (2008).
45. Rosas-Ballina, M. et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science 334, 98-101 (2011).
46. Ghia, J. E., Blennerhassett, P., Kumar-Ondiveeran, H., Verdu, E. F. & Collins, S. M. The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model. Gastroenterology 131, 1122-1130 (2006).
47. Bonaz, B. The cholinergic anti-inflammatory pathway and the gastrointestinal tract. Gastroenterology 133, 1370-1373 (2007).
48. Leib, C. et al. Role of the cholinergic antiinflammatory pathway in murine autoimmune myocarditis. Circ. Res. 109, 130-140 (2011).
49. van Maanen, M. A., Vervoordeldonk, M. J. & Tak, P. P. The cholinergic anti-inflammatory pathway: towards innovative treatment of rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 229-232 (2009).
50. Koopman, F. A. et al. Restoring the balance of the autonomic nervous system as an innovative approach to the treatment of rheumatoid arthritis. Mol. Med. 17, 937-948 (2011).
51. Huston, J. M. & Tracey, K. J. The pulse of inflammation: heart rate variability, the cholinergic anti-inflammatory pathway and implications for therapy. J. Intern. Med. 269, 45-53 (2011).
52. Yi, C. X., la Fleur, S. E., Fliers, E. & Kalsbeek, A. The role of the autonomic nervous liver innervation in the control of energy metabolism. Biochim. Biophys. Acta. 1802, 416-431 (2010).
53. Owyang, C. & Heldsinger, A. Vagal control of satiety and hormonal regulation of appetite. J. Neurogastroenterol. Motil. 17, 338-348 (2011).
54. Kreier, F. et al. Selective parasympathetic innervation of subcutaneous and intraabdominal fat-functional implications. J. Clin. Invest. 110, 1243-1250 (2002).
55. Giordano, A. et al. White adipose tissue lacks significant vagal innervation and immunohistochemical evidence of parasympathetic innervation. Am. J. Physiol. Regul. Integr. Comp. Physiol 291, R1243-R1255 (2006).
56. Wang, P. Y. et al. Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production. Nature 452, 1012-1016 (2008).
57. Cheung, G. W., Kokorovic, A., Lam, C. K., Chari, M. & Lam, T. K. Intestinal cholecystokinin controls glucose production through a neuronal network. Cell Metab. 10, 99-109 (2009).
58. Lam, C. K. et al. Activation of N-methyl-D-aspartate (NMDA) receptors in the dorsal vagal complex lowers glucose production. J. Biol. Chem. 285, 21913-21921 (2010).
59. Nakabayashi, H., Nishizawa, M., Nakagawa, A., Takeda, R. & Niijima, A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am. J. Physiol. 271, E808-E813 (1996).
60. Balkan, B. & Li, X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, R1449-R1454 (2000).
61. Vincent, K. M., Sharp, J. W. & Raybould, H. E. Intestinal glucose-induced calcium-calmodulin kinase signaling in the gut-brain axis in awake rats. Neurogastroenterol. Motil. 23, e282-e293 (2011).
62. Obici, S., Zhang, B. B., Karkanias, G. & Rossetti, L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat. Med. 8, 1376-1382 (2002).
63. Pocai, A. et al. Hypothalamic K(ATP) channels control hepatic glucose production. Nature 434, 1026-1031 (2005).
64. Pocai, A., Obici, S., Schwartz, G. J. & Rossetti, L. A brain-liver circuit regulates glucose homeostasis. Cell Metab. 1, 53-61 (2005).
65. Shimazu, T., Matsushita, H. & Ishikawa, K. Cholinergic stimulation of the rat hypothalamus: effects of liver glycogen synthesis. Science 194, 535-536 (1976).
66. Matsushita, H., Ishikawa, K. & Shimazu, T. Chemical coding of the hypothalamic neurones in metabolic control. I. Acetylcholine-sensitive neurones and glycogen synthesis in liver. Brain Res. 163, 253-261 (1979).
67. Ruiz, d. A. I, Gautam, D., Guettier, J. M. & Wess, J. Novel insights into the function of β-cell M3 muscarinic acetylcholine receptors: therapeutic implications. Trends Endocrinol. Metab. 22, 74-80 (2011).
68. Kampe, J., Tschop, M. H., Hollis, J. H. & Oldfield, B. J. An anatomic basis for the communication of hypothalamic, cortical and mesolimbic circuitry in the regulation of energy balance. Eur. J. Neurosci. 30, 415-430 (2009).
69. Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S. & Schwartz, M. W. Central nervous system control of food intake and body weight. Nature 443, 289-295 (2006).
70. Saper, C. B., Chou, T. C. & Elmquist, J. K. The need to feed: homeostatic and hedonic control of eating. Neuron 36, 199-211 (2002).
71. Erridge, C., Attina, T., Spickett, C. M. & Webb, D. J. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am. J. Clin. Nutr. 86, 1286-1292 (2007).
72. Ghanim, H. et al. Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care 32, 2281-2287 (2009).
73. Lundman, P. et al. A high-fat meal is accompanied by increased plasma interleukin-6 concentrations. Nutr. Metab. Cardiovasc. Dis. 17, 195-202 (2007).
74. Laugerette, F. et al. Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation. J. Nutr. Biochem. 22, 53-59 (2011).
75. Luyer, M. D. et al. Nutritional stimulation of cholecystokinin receptors inhibits inflammation via the vagus nerve. J. Exp. Med. 202, 1023-1029 (2005).
76. Bucinskaite, V., Kurosawa, M., Miyasaka, K., Funakoshi, A. & Lundeberg, T. Interleukin-1β sensitizes the response of the gastric vagal afferent to cholecystokinin in rat. Neurosci. Lett. 229, 33-36 (1997).
77. Gaige, S., Abou, E., Abysique, A. & Bouvier, M. Effects of interactions between interleukin-1β and leptin on cat intestinal vagal mechanoreceptors. J. Physiol. 555, 297-310 (2004).
78. Doganay, M. et al. The effects of vagotomy on bacterial translocation: an experimental study. J. Surg. Res. 71, 166-171 (1997).
79. Eckel, R. H. Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic CVD. Proc. Nutr. Soc. 66, 82-95 (2007).
80. Shoelson, S. E., Herrero, L. & Naaz, A. Obesity, inflammation, and insulin resistance. Gastroenterology 132, 2169-2180 (2007).
81. Sutherland, J. P., McKinley, B. & Eckel, R. H. The metabolic syndrome and inflammation. Metab. Syndr. Relat. Disord. 2, 82-104 (2004).
82. Gregor, M. F. & Hotamisligil, G. S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 29, 415-445 (2010).
83. Ouchi, N., Parker, J. L., Lugus, J. J. & Walsh, K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 11, 85-97 (2011).
84. Tilg, H. & Moschen, A. R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 6, 772-783 (2006).
85. Olefsky, J. M. & Glass, C. K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72, 219-246 (2010).
86. Nishimura, S. et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 15, 914-920 (2009).
87. Nathan, C. Epidemic inflammation: pondering obesity. Mol. Med. 14, 485-492 (2008).
88. Baker, R. G., Hayden, M. S. & Ghosh, S. NF-κB, inflammation, and metabolic disease. Cell Metab. 13, 11-22 (2011).
89. Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179-188 (2011).
90. Masters, S. L. et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat. Immunol. 11, 897-904 (2010).
91. Musso, G., Gambino, R. & Cassader, M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu. Rev. Med. 62, 361-380 (2011).
92. Delzenne, N. M., Neyrinck, A. M., Backhed, F. & Cani, P. D. Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat. Rev. Endocrinol. 7, 639-646 (2011).
93. Cani, P. D. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761-1772 (2007).
94. Tilg, H. The role of cytokines in non-alcoholic fatty liver disease. Dig. Dis. 28, 179-185 (2010).
95. Tilg, H. & Moschen, A. R. Inflammatory mechanisms in the regulation of insulin resistance. Mol. Med. 14, 222-231 (2008).
96. Ridker, P. M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107, 363-369 (2003).
97. Scherer, T. et al. Brain insulin controls adipose tissue lipolysis and lipogenesis. Cell Metab. 13, 183-194 (2011).
98. Howard, J. K. & Flier, J. S. Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol. Metab. 17, 365-371 (2006).
99. de La Serre, C. B. et al. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 299, G440-G448 (2010).
100. Lee, J. et al. Glucose-sensing by gut endocrine cells and activation of the vagal afferent pathway is impaired in a rodent model of type 2 diabetes mellitus. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302, R657-R666 (2011).
101. Lam, T. K. et al. Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat. Med. 11, 320-327 (2005).
102. Morgan, K., Obici, S. & Rossetti, L. Hypothalamic responses to long-chain fatty acids are nutritionally regulated. J. Biol. Chem. 279, 31139-31148 (2004).
103. Ribeiro, R. T., Lautt, W. W., Legare, D. J. & Macedo, M. P. Insulin resistance induced by sucrose feeding in rats is due to an impairment of the hepatic parasympathetic nerves. Diabetologia 48, 976-983 (2005).
104. Miller, A. W., Sims, J. J., Canavan, A., Hsu, T. & Ujhelyi, M. R. Impaired vagal reflex activity in insulin-resistant rats. J. Cardiovasc. Pharmacol. 33, 698-702 (1999).
105. Gautam, D. et al. A critical role for β cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab. 3, 449-461 (2006).
106. Liu, R. H., Mizuta, M. & Matsukura, S. The expression and functional role of nicotinic acetylcholine receptors in rat adipocytes. J. Pharmacol. Exp. Ther. 310, 52-58 (2004).
107. Cancello, R. et al. The nicotinic acetylcholine receptor α7 in subcutaneous mature adipocytes: downregulation in human obesity and modulation by diet-induced weight loss. Int. J. Obes. (Lond.) http://dx.doi.org/10.1038/ ijo.2011.275.
108. Waldburger, J. M. et al. Spinal p38 MAP kinase regulates peripheral cholinergic outflow. Arthritis Rheum. 58, 2919-2921 (2008).
109. Albuquerque, E. X., Santos, M. D., Alkondon, M., Pereira, E. F. & Maelicke, A. Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 15 (Suppl. 1), S19-S25 (2001).
110. Jo, Y. H., Wiedl, D. & Role, L. W. Cholinergic modulation of appetite-related synapses in mouse lateral hypothalamic slice. J. Neurosci. 25, 11133-11144 (2005).
111. Mineur, Y. S. et al. Nicotine decreases food intake through activation of POMC neurons. Science 332, 1330-1332 (2011).
112. Grundy, S. M. Metabolic syndrome pandemic. Arterioscler. Thromb. Vasc. Biol. 28, 629-636 (2008).
113. James, W. P. The epidemiology of obesity: the size of the problem. J. Intern. Med. 263, 336-352 (2008).
114. Vetter, M. L., Faulconbridge, L. F., Webb, V. L. & Wadden, T. A. Behavioral and pharmacologic therapies for obesity. Nat. Rev. Endocrinol. 6, 578-588 (2010).
115. Larsen, C. M. et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517-1526 (2007).
116. Goldfine, A. B., Fonseca, V. & Shoelson, S. E. Therapeutic approaches to target inflammation in type 2 diabetes. Clin. Chem. 57, 162-167 (2011).
117. Cohen, J. C., Horton, J. D. & Hobbs, H. H. Human fatty liver disease: old questions and new insights. Science 332, 1519-1523 (2011).
118. Kitagawa, H. et al. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 28, 542-551 (2003).
119. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT0 1293669?term=Targacept&rank=11 (2012).
120. Inanaga, K. et al. Acetylcholinesterase inhibitors attenuate atherogenesis in apolipoprotein E-knockout mice. Atherosclerosis 213, 52-58 (2010).
121. Handa, T. et al. Anti-Alzheimer's drug, donepezil, markedly improves long-term survival after chronic heart failure in mice. J. Card. Fail. 15, 805-811 (2009).
122. Rodriguez-Diaz, R. et al. α cells secrete acetylcholine as a non-neuronal paracrine signal priming β cell function in humans. Nat. Med. 17, 888-892 (2011).
123. Citrome, L. & Volavka, J. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. J. Clin. Psychiatry 66, 1073-1074 (2005).
124. Victoriano, M. et al. Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state. Brain Res. 1350, 167-175 (2010).
125. Teff, K. L. & Kim, S. F. Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism. Physiol. Behav. 104, 590-598 (2011).
126. Weston-Green, K., Huang, X. F., Lian, J. & Deng, C. Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur. Neuropsychopharmacol. 22, 364-373 (2011).
127. Ribeiz, S. R. et al. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. CNS Drugs 24, 303-317 (2010).
128. Strachan, M. W., Reynolds, R. M., Marioni, R. E. & Price, J. F. Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat. Rev. Endocrinol. 7, 108-114 (2011).
129. Maser, R. E., Lenhard, M. J., Irgau, I. & Wynn, G. M. Impact of surgically induced weight loss on cardiovascular autonomic function: one-year follow-up. Obesity (Silver Spring) 15, 364-369 (2007).
130. Bueter, M. et al. Vagal sparing surgical technique but not stoma size affects body weight loss in rodent model of gastric bypass. Obes. Surg. 20, 616-622 (2010).
131. Clancy, J. A., Deuchars, S. A. & Deuchars, J. 2012 GL Brown Lecture 'The Wonders of the Wanderer'. Exp. Physiol. http://dx.doi.org/10.1113/ expphysiol.2012.064543.
132. Pardo, J. V. et al. Weight loss during chronic, cervical vagus nerve stimulation in depressed patients with obesity: an observation. Int. J. Obes. (Lond.) 31, 1756-1759 (2007).
133. Bugajski, A. J. et al. Effect of long-term vagal stimulation on food intake and body weight during diet induced obesity in rats. J. Physiol. Pharmacol. 58 (Suppl. 1), 5-12 (2007).
134. Val-Laillet, D., Biraben, A., Randuineau, G. & Malbert, C. H. Chronic vagus nerve stimulation decreased weight gain, food consumption and sweet craving in adult obese minipigs. Appetite 55, 245-252 (2010).
135. Schwartz, P. J. et al. Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur. J. Heart Fail. 10, 884-891 (2008).
136. Friedman, J. M. & Halaas, J. L. Leptin and the regulation of body weight in mammals. Nature 395, 763-770 (1998).
137. La Cava, A. & Matarese, G. The weight of leptin in immunity. Nat. Rev. Immunol. 4, 371-379 (2004).
138. Maedler, K. et al. Leptin modulates β cell expression of IL-1 receptor antagonist and release of IL-1β in human islets. Proc. Natl Acad. Sci. USA 101, 8138-8143 (2004).
139. Hotamisligil, G. S., Arner, P., Caro, J. F., Atkinson, R. L. & Spiegelman, B. M. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 95, 2409-2415 (1995).
140. Leinonen, E. et al. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 166, 387-394 (2003).
141. Kanda, H. et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 116, 1494-1505 (2006).
142. Steppan, C. M. et al. The hormone resistin links obesity to diabetes. Nature 409, 307-312 (2001).